A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of MTS004 in Patients with Pseudobulbar Affect Secondary to Neurological Disorders
Latest Information Update: 26 Jun 2025
At a glance
- Drugs MTS 004 (Primary)
- Indications Emotional lability
- Focus Therapeutic Use
Most Recent Events
- 26 Jun 2025 New trial record